Table 4

Demographic features of patients with SLE myopathy and available muscle biopsy (n=16)

IDSexRaceMaximum CKStrengthEMGENMC diagnosisAntibodiesMedicationsImprovement
1FAANormalProximal muscle weaknessNormalDMANA, dsDNA, RoSteroids, HCQ–
2FC12 740Proximal muscle weaknessNon-irritable myopathyDMANA, RNP, Ro, ACA, b2GPSteroids, HCQ, CYC, MTX, IVIGNormal strength
3FC918Proximal muscle weaknessNoneDMANA, dsDNA, LAC, ACA, b2GP, RoSteroids, AZAProximal muscle weakness
4FC6900Proximal muscle weaknessIrritable myopathyDMANASteroids, HCQNormal strength
5FH93Distal muscle weaknessNon-irritable myopathyDMANA, MDA5, RoSteroids, IVIGNormal strength
6FAA6511Proximal and distal muscle weaknessIrritable myopathyDMANA, RNP, Ro, La, NT5c1ASteroids, HCQ, AZA, MMF, MTX, rituximabProximal and distal muscle weakness
7FAA18 455Proximal muscle weaknessNonePMANA, SRP, Ro, ACA, b2GP, SmSteroids, HCQ, MTX, MMF, leflunomideNormal strength
8FAA1212Proximal muscle weaknessIrritable myopathyNMANA, RNP, dsDNA, Sm, ACA, Ro, LaSteroids, HCQ, AZANormal strength
9FAA5744NormalIrritable myopathyNMANA, RNP, ACASteroids, HCQNormal strength
10FAA1908Proximal muscle weaknessNoneNMANA, dsDNA, b2GPSteroids, HCQ, AZA, MTX, MMFProximal muscle weakness
11FAA1828Proximal muscle weaknessIrritable myopathyNMANA, dsDNA, Ro, La, ACASteroids, HCQ, MTX, MMFProximal muscle weakness
12FAA1810Proximal muscle weaknessIrritable myopathyNMANA, RNP, dsDNA, Sm, RoSteroids, HCQ, MMF, IVIGNormal strength
13MAA2640NormalChronic neurogenic changesNMANA, dsDNA, ACA, b2GPSteroids, HCQ, CYCNormal strength
14FC4000NormalNon-irritable myopathyNMANA, RoSteroids, HCQNormal strength
15FAA6388NormalNon-irritable myopathyNMANA, RNP, Ro, Sm, dsDNA, LAC, ACASteroids, HCQ, AZA, BenlystaNormal strength
16MAA22 450Proximal muscle weaknessIrritable myopathyNormalANA, RNP, dsDNA, Sm, Ro, LACSteroids, CYCNormal strength

  • AA, African American; ACA, anticardiolipin antibodies; AZA, azathioprine; b2GP, anti-beta-2 glycoprotein antibodies; C, Caucasian; CK, creatine kinase; CYC, cyclophosphamide; DM, dermatomyositis; dsDNA, anti-double-stranded DNA antibodies; EMG, electromyography; ENMC, European NeuroMuscular Centre; F, female; H, Hispanic; HCQ, hydroxychloroquine; ID, identification; IVIG, intravenous immunoglobulin; LAC, lupus anticoagulant; M, male; MDA5, Melanoma Differentiation-Associated protein 5; MMF, mycophenolate mofetil; MTX, methotrexate; NM, necrotising myopathy; PM, polymyositis; RNP, anti-ribonucleoprotein antibodies; Sm, anti-Smith antibodies; SRP, Signal Recognition Particle.